Podcasts about Remission

Alle Informationen zur Carnivoren Ernährung unter www.carnitarier.de. ______________________________________________ Herzlichen Dank an unsere WERBEPARTNER: www.carnivoro.eu: Supplemente rund um die Carnivore Ernährung Mit dem Gutscheincode CARNITARIER erhältst du 10 % Rabatt auf deinen ersten Einkauf! Affiliate Link: www.carnivoro.eu/carnitarierinwww.kaufnekuh.de: Fleisch aus artgerechter Haltung mit fairen Preisen für Landwirte Mit dem Gutscheincode CARNITARIER erhältst du 10 € Ermäßigung auf deinen Einkauf ab 50 €. www.mindful-meat.com: Hochwertiges Hirschfleisch aus den Wäldern Deutschlands. Mit dem Gutscheincode CARNITARIER erhältst du 10 € Ermäßigung auf deinen Einkauf. www.pemmican-shop.de: Europas einzige originale Survival Beef Bar – Made in Germany. Mit dem Gutscheincode CARNITARIER erhältst du 10 % Ermäßigung auf deinen ersten Einkauf.www.theminerals.de: Beste Elektrolyte für die Umstellung auf Keto und für Carnivoren, die viel Sport treiben. Mit dem Gutscheincode CARNITARIER erhältst du 10 % Ermäßigung auf deinen Einkauf. ______________________________________________Folge 208: Carnivore gegen Autoimmunerkrankungen – Bastian HölscherCarnivore ist eine Eliminationsdiät. Wer Probleme mit Autoimmunerkrankungen oder chronischen Magen-Darm-Erkrankungen hat, sollte möglichst viele Lebensmittel eliminieren, die einem nicht guttun. Bastian Hölscher, funktionieller Mediziner, hat selbst seine chronisch entzündliche Darmerkrankung mit einer Paleo-Ernährung, also nahezu einer Carnivoren Ernährung in Remission gebracht. Bei jedem Lebensmittel sollte man sich fragen, welche Nährstoffe man daraus ziehen kann und welchen Schaden es im Körper anrichten könnte. Kakao hat zum Beispiel einen sehr hohen Gehalt an Oxalsäure, die sich in unserem Körper ansammeln kann. Ausleitungssymptome von Giftstoffen, auch von Schwermetallen können aber auch Probleme hervorrufen. Kohlenhydrate können gezielt eingesetzt werden, je nachdem, wie stark sie durch Bewegung wieder abgebaut werden. Wer Carnivore macht, der denkt einfach um. Er verlangt nicht extra Substanzen oder Medikamente gegen die Beschwerden, sondern er streicht Lebensmittel, die die Beschwerden verursachen. Man geht also der Ursache auf den Grund. Carnivore ist im Grunde wie ein Fasten, aber eben eine Form, die man auf Dauer durchführen kann und die einem alle Nährstoffe liefert.Ihr könnt Bastian Hölscher erreichen unter www.praxishoelscher.de oder auf  Instagram unter @bastianhoelscher._____________________________________________Fleischzeit ist der erste deutschsprachige Podcast rund um die carnivore Ernährung. Hier erfahrt ihr Tipps zur Umsetzung des carnivoren Lifestyles, wissenschaftliche Hintergründe zur Heilsamkeit sowie ökologische und ethische Informationen zum Fleischkonsum. Eine Übersicht über alle Folgen findet ihr hier: www.carnitarier.de/fleischzeitpodcastAndrea Siemoneit berichtet nach über sechs Jahren carnivorer Ernährung über ihre Erfahrungen und Erkenntnisse. Außerdem interviewt sie andere Carnivoren und Wissenschaftler.Ihr findet sie auf Instagram unter @carnitarier.deHandbuch der Carnivoren Ernährung: www.carnitarier.eu Haftungsausschluss:Alle Inhalte im Podcast werden von uns mit größter Sorgfalt recherchiert und publiziert. Dennoch übernehmen wir keine Haftung für die Richtigkeit, Vollständigkeit oder Aktualität der Informationen. Sie stellen unsere persönliche subjektive Meinung dar und ersetzen auch keine medizinische Diagnose oder ärztliche Beratung. Dasselbe gilt für unsere Gäste. Konsultieren Sie bei Fragen oder Beschwerden immer Ihren behandelnden Arzt.

„Super, wir haben eine Lösung für dich und jetzt schaffen wir das zusammen.“ Eine gute Weichenstellung beginnt bei jungen CED-Patienten schon in der Klinik, denn es sind „schwerste Erkrankungen, welche die Kinder lebenslang begleiten", erinnert Dr. Christoph Schick, leitender Oberarzt und Sektionsleiter der Kinder-Gastroenterologie am Josefinum in Augsburg. Natürlich haben die allermeisten Bauchweh-Patienten funktionelle Bauchschmerzen. Doch bei Red Flags wie Wachstumsstörungen, blutigem Stuhl oder chronischem Durchfall sollte man hellhörig werden. Einen hohen Vorhersagewert hat nach dem Kleinkindalter das Calprotectin. Wiederholt niedrige Werte sprechen gegen M. Crohn, Colitis ulcerosa oder eine unspezifische Colitis (CED-u). Dann erübrigt sich auch eine Koloskopie. Mit einer Ernährungstherapie lässt sich einiges erreichen, Vitamin D hilft, den Erkrankungsverlauf zu stabilisieren und die „Trickkiste“ der Medikamente ist gut gefüllt. Wird eine immunsuppressive Therapie erforderlich, ist „ein gut geimpftes Kind eine enorm gute Grundvoraussetzung“. Ein scheinbar banaler Infekt kann schließlich schnell ernst werden. Die gute Nachricht: Die allermeisten Kinder mit CED können inzwischen in Remission gebracht werden. **Muster anfordern:** Eine Musteranforderung des genannten Produktes ist für Ärzte jeweils in einem Zeitraum von 8 Wochen ab dem ersten Erscheinungstag der Podcastfolge möglich: https://www.infectopharm.de/ma/quimbo/ Weitere Informationen zu Quimbo Sirup Fachinformation Quimbo Sirup. Pflichttext Quimbo Sirup. Packungsbeilage Quimbo Sirup. Fachinformation Quimbo Tropfen. Pflichttext Quimbo Tropfen. Packungsbeilage Quimbo Tropfen. Patientenratgeber Husten zum Lesen oder als Hörbuch. **Link zum Transkript:** https://www.infectopharm.de/consilium/podcast/podcast-paediatrie/ **Kontakte:** Feedback zum Podcast? podcast@infectopharm.com Homepage zum Podcast: www.infectopharm.de/consilium/podcast/ Für Fachkreise: www.wissenwirkt.com und App „Wissen wirkt.“ für Android und iOS Homepage InfectoPharm: www.infectopharm.de **Disclaimer:** Der _consilium_ – Pädiatrie-Podcast dient der neutralen medizinischen Information und Fortbildung für Ärzte. Für die Inhalte sind der Moderator und die Gäste verantwortlich, sie unterliegen dem wissenschaftlichen Wandel des Faches. Änderungen sind vorbehalten. **Impressum:** _consilium_ ist eine Marke von InfectoPharm Arzneimittel und Consilium GmbH Von-Humboldt-Str. 1 64646 Heppenheim Tel.: 06252 957000 Fax: 06252 958844 E-Mail: kontakt@infectopharm.com Geschäftsführer: Philipp Zöller (Vors.), Michael Gilster, Dr. Markus Rudolph, Dr. Aldo Ammendola Registergericht: Darmstadt – HRB 24623 USt.-IdNr.: DE 172949642 Verantwortlich für den Inhalt: Dr. Markus Rudolph

Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author, Professor Sundar Jagannath, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the Tisch Cancer Institute. He also serves as Network Director for the Center of Excellence for Multiple Myeloma, and he is an internationally recognized expert in the field of multiple myeloma. Today, we will be discussing the article titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Thank you for speaking with us, Professor Jagannath. Dr. Sundar Jagannath: Thank you for having me, Dr. Davide Soldato. It is a pleasure to be here. JCO is a highly recognized journal among the oncologists, so I am very happy and privileged to be here today. Dr. Davide Soldato: Thank you so much for being with us. So, I wanted to start a little bit with the rationale of the study and the population that was included in the study. So, the trial that we are discussing, CARTITUDE-1, was already published before, and we observed very good results with a single infusion of cilta-cel. So we had previously reported a median progression-free survival of 30 months, and median overall survival was not reached. So, I just wanted to ask you if you could guide us a little bit into the population that was included in the study and also explain a little bit to our listeners what is the drug that we are discussing, cilta-cel. Dr. Sundar Jagannath: It is a CAR T-cell. This is a patient's own lymphocytes, which goes through apheresis and is sent to the company, where they modify it and introduce the B cell receptor. In this case, you know, there is a heavy chain gene receptor for the BCMA, and in cilta-cel, there are actually two receptor sites on each molecule, or there are two binding domains on each receptor molecule. So, it is considered to be quite efficacious. As you reported, the earlier results that the patients who participated, 97% of the patient responded. Now, you asked about the patients who participated in the clinical trial. This clinical trial was conducted between July of 2018 and October of 2019. At that time, this was a phase 1b/phase 2 trial, and the whole idea was to take patients who had relapsed all the available treatment regimen so that these patients were considered to have, in the unmet medical need situation. So, what does that entail? That means the patient should have been exposed to a proteasome inhibitor, to an immunomodulatory molecule, and to an anti-CD38 monoclonal antibody and should have received at least three or more prior lines of therapy and should be actually progressing on their last line of therapy. So with that requirement, if you look at it, the median number of prior therapy on the patients who participated was actually six. So patients were heavily pretreated. They had exhausted all available treatment options. So, they can participate in this clinical trial. And if not, there have been real-world evidence, such as LocoMMotion, which had reported what is the outcome for such a patient if they were treated outside of this clinical trial, if they were treated with the then available regimen. Their median progression free survival would have been only 3 months, and most patients would have lost their life within a year. So, this was truly an unmet medical need with patients in a very difficult clinical situation. Let's put it that way. So, those were the patients who participated in this particular trial. Dr. Davide Soldato: Thank you very much. And as we mentioned before, the results that were obtained in this clinical trial were really very interesting. And now, in this issue of the Journal of Clinical Oncology, you are reporting data with a longer follow up. So we are actually at more than 5 years of follow up for the patients included in this trial. So, I just wanted a little bit of insight into why you decided to report these long-term outcomes and what type of information do you think you could provide with this study to the medical community? Dr. Sundar Jagannath: This is very important because this was a clinical trial that was done in patients who were, as I said, in unmet medical need. Most of the patients had prior stem cell transplantation, had gone through a proteasome inhibitor. Many of them have had both Velcade and carfilzomib treatment. Most of them had been exposed to lenalidomide and pomalidomide. And as required, all of the patients had to have had prior exposure to anti-CD38 monoclonal antibody or daratumumab. So, the patients were heavily pretreated. Typically, TIL CAR T-cells came into the field at this particular moment, until then, we were developing small molecules, and they usually would have a PFS of 3 months and median life expectancy of a year, the overall response rate of 30%, and that is how, if you look back, that is how carfilzomib was approved, that is how pomalidomide was approved. So, the drugs which were approved, including daratumumab, you know, the response rate was in the same ballpark. So you would see that most agents, single agents, would have had a response rate in the neighborhood of 30%, the progression-free survival would have been between 3 to 5 months or 6 months at the most, and the life expectancy was short. And here comes a drug, and when I was following the patients at Mount Sinai, I found that there were a subset of patients, they got one-time treatment and they were in complete remission, no trace of cancer with annual evaluation with PET CT and bone marrow evaluation for MRD. So, I said this is remarkable, and this needs to be reported. And I went to the Janssen and company, and they agreed to review the entire experience. This is remarkable that 32 of the 97 patients, or one third of the patients, were alive and progression-free. This is unheard of for any clinical trial until now, that the patient will be progression-free, one third of the patients on a clinical trial will be progression-free, in the late stage of their disease. So that is the most important impact. And that is why this 5-year follow-up results were presented. Dr. Davide Soldato: Thank you very much. That was very clear. And as you said, we are speaking about a population that was heavily pretreated, that had exhausted all type of treatment options outside of a clinical trial. And as you said, one third of the patients was alive and progression-free after 5 years from being included and infused inside of the study. So, considering this population that, as we said, had received all treatment options, I was wondering if you observed any kind of differences in terms of disease characteristics when looking at these patients that had exceptional response, so, alive and progression-free at 5 years, and the patients that sadly had developed a progression after the infusion in the study. Dr. Sundar Jagannath: This is very important because we wanted to see who are the patients who are having this exceptional outcome. And we looked at all the 97 patients. If we look at all the patients, we saw that there were initially, out of the 97, 17 patients died earlier in the disease course due to treatment related complications, etc. But there were about 46 patients who had progression of disease and 32 patients, or one third, were alive without progression of disease. Then we looked at the 46 patients who had progression of disease. Of them, we found that 30 had disease progression and its complication, and there were actually 13 patients who were still alive even after progression of disease. So we decided to compare these 46 patients who had progression of disease versus 32 patients who had no progression of disease to see what is the difference. To our surprise, the age was similar, male, female distribution was similar. High-risk cytogenetics, which we would have thought, you know, that is why we say high-risk disease, the term, high-risk cytogenetics was equally distributed. That was really a surprise. Number of lines of prior therapy, number of exposure to drugs, all of that was the same. So that was also interesting. But a theme did emerge. Patients, in general, tend to have lower burden of disease who had the exceptional outcome. But there is one which we considered as bad, the extramedullary disease. Multiple myeloma being a blood cancer, it is usually in the bone marrow. When it starts growing outside of the bone marrow, the extramedullary disease, usually it portends poor prognosis. But we were surprised that actually there were an equal number of extramedullary disease patients even in the long-term survivor as those who had progressed of disease. So the most important takeaway was patients who had lower burden of disease, they had less number of myeloma cells in their bone marrow, percentage wise, and the soluble BCMA level was lower. Soluble BCMA is an indirect measure of the amount of plasma cells in the patient's body. It is like a tumor burden. So they were low. So, this was an important finding because it has future ramification, as you can understand. If this treatment is made available earlier in the disease course of the patients, where we are able to control the disease better, then more patients are likely to have such wonderful outcomes as one third of the patient experience in the late stage of the disease. Dr. Davide Soldato: So, you already mentioned soluble BCMA as a marker of potentially better prognosis as being correlated to a lower volume of disease. I was wondering if you could give us some more information about the biomarkers that you evaluated in the study. For example, you evaluated a little bit the CAR T expansion kinetics and also some others that I think could be interesting and could point to some population that experienced such important benefit. Dr. Sundar Jagannath: That is a very important point because CAR T-cell, it is a live cell and its efficacy depends upon how well the CAR T-cell is going to function. And then, you know, the patient undergoes apheresis. This is a patient's own lymphocyte. So first and foremost is who would generate good CAR T-cell. Those who have plenty of lymphocytes at the time they are coming for apheresis. This is likely to happen earlier in the course of the disease than in patients who have gone through numerous lines of therapy and exhausted. So, in this particular trial, of course this was in late stage of the disease, and so we were able to show patients who had lower number of T cell in circulation, and the way to measure is if they had more neutrophils and less lymphocytes. So that is what is called as a higher T cell over neutrophil, they did better. If they have more neutrophil than T cells, then they did not do well. So, procurement. The second one is also whether the T cells are more naive, you know, not exhausted T cells. So more naive T cells, if you are able to procure from the patient, they did very well. Now, after the CAR T-cell manufacture, then the expansion, when you put it back into the patient, if the T cells expand very well, so that the effector, that is the CAR T-cells to the tumor ratio is good, so there are more effector cells, the CAR T was able to expand and the amount of tumor was less, then the efficacy was very, very good. As I said, the patients in this group, those who had a lower burden of disease, they did better, and that is because of the CAR T-cell expansion, so the effector to the target ratio was favorable. So that is another important. And then there are also the type of CAR T-cells, having CD4 T cells with central memory phenotype at the peak expansion also makes a difference. So all of that matters. But this is important because the efficacy of the CAR T-cell, it is persistent, long persistent and keeping the cancer down. Its ability to get rid of the cancer completely at the first go around because usually we are not able to detect the CAR T-cells beyond 6 months in the majority of patients and very rarely after a year or two. So it is very uncommon to find the CAR T-cells in circulation or even in the regular bone marrow evaluation. So, efficacy, the expansion, having naive T cells, having good effector to target ratio and more central memory kind of T cell, because if it is all effector T cell, they will get quickly utilized and get exhausted, whereas the central memory cells can expand more and give more effective CAR T-cells. Dr. Davide Soldato: Thank you very much. I was wondering if you could guide us a little bit into what is your opinion regarding the positioning of CAR T-cells given all of these logistics that is necessary compared, for example, with bispecific antibodies against BCMA, which have the same target, but they do not have all of these logistics before being administered to the patient. Dr. Sundar Jagannath: That is a very important question, how to sequence these treatments now that we have two BCMA-directed CAR T-cells available. We have three BCMA-directed bispecific and one GPRC5D-directed bispecific antibodies are available. And so the question comes in for at least the currently approved CAR T-cell therapy, there is an obligatory time. You have to go through apheresis and you have to ship to the company, and there is a manufacturing time, roughly about 2 months before they can receive it. During that time, you want to make sure the patient's disease is under control. So that is a given. There are several ways to look at it when we evaluate the patient and talk to the patient. One good thing is now the two CAR T-cells which are approved, one is cilta-cel we talked about, and the other one is ide-cel. Ide-cel is approved in earlier line of therapy, two or more prior lines of therapy, and cilta-cel is approved in patients who have failed one line of therapy and who are lenalidomide refractory. So, the treatment of CAR T-cell is available earlier. And as I said, when you administer CAR T-cell earlier, you are able to keep the disease burden down, and it is a one and done deal. There is a better quality of life for the patient, and you are able to produce long, durable remission and potentially a cure. Now coming to the bispecific, they are currently available in later lines of therapy. So if you look at it from a patient's perspective, you can use the CAR T-cell earlier and then go through the bispecific therapy. But if the patient comes with relapsed refractory myeloma and has not used the CAR T-cell therapy and has not used the bispecific therapy, then the physicians have to decide which one they want to use. If somebody's disease is rapidly progressing and they need immediate tumor reduction and they have already exhausted all available therapy, then going through BCMA bispecific therapy is quite appropriate. And secondly, CAR T-cell therapy is generally given to somewhat physically more fit patients, whereas bispecific therapy, because you are giving antibody at step-wise dosing in this patient, and you have the ability to stop at any particular dose and then come back and redose, whereas CAR T is, you just give it to them one time, you have a lot more control. So intermediate frail or even frail patients can go through bispecific therapy, whereas it would not be in the best interest of the patient to go through a CAR T-cell therapy when they are frail. So that is another important point. But from the information available, when the patient goes on a BCMA bispecific therapy and they start progressing on treatment, usually it is their T cells are exhausted or the BCMA is no longer expressed on the tumor cells. So coming with CAR T-cell later on is usually not effective, whereas giving CAR T-cell earlier, if the patient relapses later, they have good T-cell function and most of the time the BCMA is still expressed. So you are able to give the BCMA to the maximum benefit by using the CAR T first and BCMA later. So if somebody asked me how to sequence this, just off the bat, you will say CAR T first, BCMA bispecific second. But as I said, there are unique situations. Then there is another potential that is happening. You can change the target. You can use a BCMA against GPRC5D to reduce the tumor, and then go ahead and consolidate it with a CAR T-cell therapy. That is also possible. You are changing the target from GPRC5D to BCMA, the tumor is already down, so the patient is likely to benefit. So these are all newer treatment options which have become available to the physician. So they will have to look at individual patients and decide what is the best course of action for that patient. Dr. Davide Soldato: So, I just wanted to close a little bit with your opinion about how these results translate into clinical practice. So considering this outstanding 5-year data that we have seen, one third of the patients who are alive and progression-free after a single infusion of cilta-cel, do you think that we could start to think about functional cure even in patients who have a diagnosis of relapsed refractory multiple myeloma? Dr. Sundar Jagannath: My feeling is this is important because in this particular study which is published, 12 patients who were followed at Mount Sinai out of the 32 patients who are alive and progression-free, 12 were followed at Mount Sinai. And they were evaluated every year with bone marrow MRD testing by clonoSEQ in 11 of the 12 patients, and one was by multiparametric flow cytometry. So most of them were 10 to the minus 6, not even one in a million cancer cells, and all of them had functional imaging, which is called PET CT every year. So these were patients who had no evidence of disease that we could detect with the technology available today, serologically, in the bone marrow, or anywhere else in the body with a PET CT. They were found to be disease free after a single infusion of cilta-cel. So, that would be almost to the definition of a cure because if you look at cure as a definition for any cancer, cure is defined as a state of complete remission with no trace of cancer that persists over a period of 5 years or longer without maintenance. And that will be applicable for breast cancer, lymphoma, leukemia. So it is a general statement. And if we use that in myeloma too, then I could say that these 12 patients from my center, we proved that they are cured of their myeloma. They are not functionally cured. You've got to remember, there is only cure. That was the definition across all diseases. So there is nothing like a functional cure. They are cured of myeloma. So is myeloma curable? This is the first time we are looking at that. We do know, every physician treating myeloma that there are patients out there, 10 year and beyond, without evidence of disease. This has been published by University of Arkansas, Bart Barlogie's group, who has been saying that myeloma is a curable disease for a long time. And many others have shown long-term follow up. But this one in a late stage disease, we were able to show that they were one treatment with no maintenance. All other studies have been in newly diagnosed myeloma patients. Nobody has shown in late relapse patients on a clinical trial a third of the patient will be progression-free. And 12 of them who were studied were actually disease free. So they were cured of the disease. So if we accept that, then the next question is, first step towards cure is achieving complete remission. They should have no monoclonal protein by any technology you want to use, no measurable residual disease using next gen sequencing or clonoSEQ, and functional imaging whole body PET CT or whole body MRI. So that is important, definition of the complete remission. And then it has to be sustained. That is something the IMWG and IMS, International Myeloma Society, they will have to come together for a consensus. How many years should they be followed and should be in this kind of status with no trace of cancer? Is it, 3 years are enough? 4 years enough? 5 years is enough? For me, I said in this paper, 5 years is a good definition for achieving a potential cure. Then you use the term 'functionally cured'. I have a problem with functionally cured and operationally cured or whatever. Functionally cured was originally put out by Paiva from Spain. There were 8% of newly diagnosed myeloma patients who have, after they go get treated, they will have an MGUS like phenomenon, a small amount of paraprotein detectable, and they are only 8%. And he said that these patients could be off treatment and the disease does not progress. But the problem is when you are giving treatment like maintenance therapy continuously until progression, you do not know exactly who is in the MGUS situation. So you have to have done sophisticated flow cytometry like Paiva did, and it is not quite clinically applicable. So functionally cured applies only for 8% of the people, so it should go out of the vocabulary. Then you can say 'operationally cured'. These are the patients traditionally Bart Barlogie and others showed that they have a large number of patients who have been followed for 10 years with no recurrence of disease, not on treatment. But in those days, they did not have MRD PET CT and all of them done systematically. So that is why they had to come up with a situation where they said they were operationally cured. So yes, myeloma patients have been cured since auto transplant was introduced. I completely agree. It is not new to the CAR T-cell therapy. But the beauty of the CAR T-cell therapy was it was in relapsed refractory myeloma, unmet medical need, number one. Number two, they were studied systematically. It was a clinical trial adjudicated by FDA and EMA for drug approval, cilta-cel was approved. So these patients were carefully followed, and it was a multi-center study. And in that group of patients, we were able to show patients- So, I think this would indicate cure is a reality in myeloma, and as these kind of treatments, immunologic treatment, either it is a CAR T-cell therapy or BCMA bispecific or whatever, there is a chance more patients are likely to be cured, and these treatments have to move forward and so that we are looking towards a cure. That is the beauty of it, and I just thank you for asking and also throwing in this so-called functionally cured, which people like to use casually, and I say it is time to talk more cure and not stuck with functionally cured because that does not allow the field to progress. Dr. Davide Soldato: Thank you very much. That was very interesting. Dr. Sundar Jagannath: And provocative. Dr. Davide Soldato: A little bit, but I think that we needed to close the podcast with this kind of reflection coming from someone who is an expert in the field, as you are. So, I really wanted to thank you for joining us today and for sharing more on your article, which is titled, "Long-Term Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." If you enjoy our show, please leave us a rating and a review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. Dr. Sundar Jagannath: Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Interview with Giselle Corbie, MD, MSc, Associate Editor of JAMA Internal Medicine, and Lynda H. Powell, PhD, author of Lifestyle Intervention for Sustained Remission of Metabolic Syndrome: A Randomized Clinical Trial. Hosted by Eve Rittenberg, MD. Related Content: Lifestyle Intervention for Sustained Remission of Metabolic Syndrome

Interview with Giselle Corbie, MD, MSc, Associate Editor of JAMA Internal Medicine, and Lynda H. Powell, PhD, author of Lifestyle Intervention for Sustained Remission of Metabolic Syndrome: A Randomized Clinical Trial. Hosted by Eve Rittenberg, MD. Related Content: Lifestyle Intervention for Sustained Remission of Metabolic Syndrome

All Praises to the Most High A'HÂYÂH!!!And YASHAYA!!!Yashana in the Highest!!!Call or Text the Prayer, Praise, Testimony and Discussion line!!! 24 hours a day 7 days a week!!!(407)476-7163 !!!We are a Husband and Wife Team!!!Evangelists James and Louise Eads!!!We are Street Evangelists and Online Ministers too. Preaching the Gospel of Christ Yashaya and our Heavenly Father A'HÂYÂH!!!Repent and Follow Yashaya!!! And be Baptized for the Remission of Sins and for the sins of your forefathers!!!Thank you everyone that gives to this Ministry to get the Gosple of Yashaya across the World.We have Pay Pal and Cash App PayPal:Email address is watchmanstreetministry@gmail.com Thank you for your prayers and support https://www.paypal.me/JamesEadsCash App: $Evangelists7

On Par sits down with Sam Eppy to unpack Juju's Mission to Remission, a 501(c)(3) charity golf tournament for families fighting pediatric leukemia. This year's event is set for November 21 at Bay Tree in Melbourne, Florida!In this episode:• How year one raised about $50K for families facing pediatric cancer, and why the team formed a 501(c)(3) to do it right• How grants and matching gifts opened up after going nonprofit, plus simple steps to qualify• Smart charity golf sponsor mix vs foursome pricing that fills the field and funds the cause• Crowd-favorite activations that lift donations, drone golf ball drop, AR-15 golf-ball launcher, fun putting games.• Easy volunteer roles and swag ideas that keep the tournament smooth and profitable• How to plan a charity scramble at your course, registration flow, day-of timeline, checkout tipsIf this story moved you, help us help more kids. Join us at Bay Tree in Melbourne on November 21, sponsor a hole, or share this with a golfer who cares. Watch the full episode, hit Subscribe, and leave a comment with one small way you can pitch in!#golf #golftournament #charitygolf #charity  #pediatriccancer  #onparpodcast  #melbourneflorida #fundraiser #golfcourse #golfpodcast #podcastshow #SamEppy

(00:00:00) Navigating Disruptions and Resilience (00:04:28) Leadership Challenges in Uncertain Times (00:07:03) Communication: The Key to Team Performance (00:11:17) Understanding Generational Differences in the Workplace (00:13:17) The Role of Empathy in Leadership (00:15:34) Building Resilience in Leadership (00:20:45) Connecting Daily Work to a Larger Purpose In this conversation, Maureen O'Brien, CEO of the Global Wisdom and Leadership Forum, discusses the challenges leaders face in today's uncertain business climate. She emphasizes the importance of resilience, effective communication, and empathy in leadership.O'Brien shares insights on generational differences in the workforce and the need for leaders to connect their teams' daily work to a larger purpose. The discussion highlights practical steps leaders can take to foster a culture of innovation and adaptability within their organizations.Thank you for listening and please take a moment to subscribe, rate, and review our show on your favorite app.To get a hold of us here at Keepin' The Lights On, please email: podcast@graybar.comYouTube Version: https://youtu.be/NEufR_-TZcAGlobalWLF Webiste:  www.globalwlf.comHBDI (Herrmann Brain Dominance Instrument):  https://www.globalwlf.com/leadership-developmentMaureen's Linkedin: https://www.linkedin.com/in/maureenobrienceo/Maureen's book:  “26 Points of Light” – Illuminating One Cancer Survivor's Journey from Diagnosis to Remission”   https://www.amazon.com/Points-Light-Illuminating-Survivors-Diagnosis/dp/1734959010In 26 Points of Light, supporters across O'Brien's community of care—family, friends, coworkers, extended family, and even medical staff—offer their unique experiences of the journey they walked with Maureen and share the knowledge and inspiration they gained along the way. You'll learn:How each caregiver was uniquely impacted by the diagnosisWhy the nurse–patient relationship is so important to anyone undergoing recoveryHow to "quarterback" a loved one's caregiving teamWhy true belief in cancer remission is crucial for both patient and support systemWhy whatever you have to give is exactly the right thing to offerWith its multitude of voices and perspectives, 26 Points of Light is a cancer caregiver book like no other. If someone you love has received an unexpected diagnosis, this book will help you deliver constant, crucial encouragement. And for those experiencing it firsthand, it will illuminate their true impact on others and remind them that they are not alone.Maureen's BIO: Maureen O'Brien is a nationally recognized speaker, bestselling author, and the CEO of the Global Wisdom & Leadership Forum. With over 30 years of experience in leadership, sales, and business ownership—including in construction and the skilled trades—Maureen brings a unique, real-world perspective to the challenges leaders face today.A Stage IV cancer survivor and the author of “26 Points of Light: Illuminating One Cancer Survivor's Journey from Diagnosis to Remission,”  Maureen's personal story fuels her professional mission: helping others lead with courage, clarity, and resilience. She is the creator of Point of Light Leadership™, a practical framework for navigating change and inspiring teams in high-stakes environments.Her core message is clear: Resilient leadership isn't just about bouncing back—it's about lighting the way forward for others.ALL PROCEEDS OF THE BOOK GO TO CANCER RESEARCH AND PATIENT CARE. TakeawaysResilience is crucial for leaders in today's challenging environment.Effective communication is key to resolving team dynamics.Leaders must practice self-awareness to understand their impact on teams.Empathy has become a vital skill for effective leadership. Generational differences can create challenges in the workplace.Leaders should encourage innovation and risk-taking among their teams.Understanding the bigger picture can motivate teams to perform better.Leaders need to connect daily tasks to a larger purpose.Continuous learning is essential for resilient leadership.Taking a pause can help leaders break free from preconceived notions.

In the ongoing search for an HIV cure, promising evidence suggests that early treatment of infants might help achieve lasting HIV remission: the IMPAACT P1115 study is designed to investigate that potential. We talk to a lead investigator about what we know so far.Read the full article: www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00189-4/fulltextContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

All Praises to the Most High A'HÂYÂH!!!And YASHAYA!!!Yashana in the Highest!!!Call or Text the Prayer, Praise, Testimony and Discussion line!!! 24 hours a day 7 days a week!!!(407)476-7163 !!!We are a Husband and Wife Team!!!Evangelists James and Louise Eads!!!We are Street Evangelists and Online Ministers too. Preaching the Gospel of Christ Yashaya and our Heavenly Father A'HÂYÂH!!!Repent and Follow Yashaya!!! And be Baptized for the Remission of Sins and for the sins of your forefathers!!!Thank you everyone that gives to this Ministry to get the Gosple of Yashaya across the World.We have Pay Pal and Cash App PayPal:Email address is watchmanstreetministry@gmail.com Thank you for your prayers and support https://www.paypal.me/JamesEadsCash App: $Evangelists7

Sechs Jahre pflanzliche Ernährung und kein Zurück? In dieser Folge spreche ich ehrlich über das, was viele verschweigen: warum Ernährung nicht nur hilft, sondern auch Stress machen kann, gerade bei Morbus Crohn udn Colitis Ulcerosa. Ich nehme dich mit in meine sechs Jahre zwischen Darmriss, Rückverlegung und Remission und teile fünf Einsichten, die mein Denken über Essen, Energie und Entzündung komplett verändert haben.

A new MP3 sermon from Carey Baptist Church is now available on SermonAudio with the following details: Title: Luke 24 PART II That Repentance And Remission Of Sins Should Be Preached Subtitle: Book Of Luke Speaker: Pastor Benjamin Donahue Broadcaster: Carey Baptist Church Event: Radio Broadcast Date: 10/30/2025 Bible: Luke 24:38-53 Length: 15 min.

In this hope-filled episode of the UnabridgedMD Podcast, Dr. Isabelle Amigues sits down with Cliff—a former patient—to trace his journey from sudden, debilitating pain and months of uncertainty to full remission and a return to the life he loves. After being dismissed and delayed elsewhere, Cliff found UnabridgedMD, received an accurate diagnosis of polymyalgia rheumatica (PMR), and followed a clear, compassionate plan: calm the “fire” of inflammation, treat decisively, and taper safely. Within a few months he was off steroids, symptom-free, and cleared to travel to Africa—proof that partnership, precise listening, and a treat-to-target mindset can change everything.

In this bonus episode, Dr. Kahn sits down with Dr. William Hsu, Chief Medical Officer at L-Nutra (Prolon) and former Harvard Medical School faculty member, for a fascinating look at how fasting can help put Type 2 diabetes into remission. Dr. Hsu explains why muscle mass is crucial for managing diabetes — it's where glucose gets absorbed — and how the Fasting Mimicking Diet (just five days a month for six or more months) can lead to incredible results. The program not only supports blood sugar control but also helps preserve muscle and target belly fat, which is exactly what you want from healthy weight loss. Check out the programs mentioned in the episode:

For full show notes visit https://www.janeperrone.com/on-the-ledge/2025/10/24/episode-306-the-atlas-of-deadly-plants My new book The Atlas of Deadly Plants is out this week, published by Greenfinch, so I thought I'd celebrate by offering up a series of mini-podcast episodes digging into some of the themes and facts from the book - just in time for Halloween! In this mini-ep I talk about two terms you might hear in connection with plant poisonings - treacherous remission and therapeutic range. Want to buy a copy right now? Click here. Check out Legends of the Leaf, my book on houseplants and my houseplant cards Houseplant Gardener in a Box here. Support On The Ledge on Patreon: https://www.patreon.com/ontheledge Follow Jane Perrone on Instagram: https://www.instagram.com/j.l.perrone

Mel Burbank, founder of Alcohol Free Females, shares her sobriety journey and her mission to empower high-performing women to embrace an alcohol-free lifestyle through reinvention. She discusses the concept of spontaneous remission and how she teaches clients to achieve sobriety through her program.With a background as a certified integrative health and CBT coach, a longtime single mom, and a female entrepreneur, Mel left alcohol behind to create her dream life. With an MBA and over 20 years of experience in women's wellness, fitness, and identity transformation, she provides her clients with the framework to build a life on their own terms-with clarity, confidence, and zero compromise.You can connect with Mel Burbank on Instagram @alcoholfreefemales

DisclaimerThis podcast represents the opinions of Your Life, Reset and guests to the show. The content here should not be taken as, or considered a substitute for, medical advice, diagnosis and/or treatment, for either yourself or others, including but not limited to individuals you may be treating. The content here is for informational purposes only, and because each person is unique, please consult your medical provider for any medical questions or if you have, or suspect you have, a medical problem. In no way does listening, reading, emailing or interacting on social media with our content establish a doctor-patient relationship.Views and opinions expressed in the podcast are our own and do not necessarily represent that of our places of work. While we make every effort to ensure that the information we are sharing is accurate, we welcome any comments, suggestions, or correction of errors.Privacy is of the utmost importance to us. Where appropriate, the people, places, and scenarios mentioned in the podcast may be changed to protect patient confidentiality.This podcast should not be used in any legal capacity whatsoever, including but not limited to establishing “standard of care” in a legal sense or as a basis for expert witness testimony. No guarantee is given regarding the results or accuracy of any statements or opinions made on the podcast.This entire disclaimer also applies to any guests or contributors to the podcast. Under no circumstances shall any guests or contributors to the podcast, or any employees, associates, or affiliates of Virta Health be responsible for damages arising from use of the podcast.If you find any errors in any of the content, please send a message through our form here: https://virtahealth.zendesk.com/hc/en-us/requests/newThis podcast is owned by Virta Health. The contents of Your Life, Reset and show notes are all copyrighted Virta Health. All posts, podcasts, and show notes that are distributed to the public for free can be re-distributed via hard copy or electronic copy for free ONLY if Virta Health is included as the acknowledged author within the actual media that is re-distributed.Your Life, Rest: privacy policy (link) and terms and conditions (link).

SummaryThe conversation delves into the importance of discerning truth within the Christian faith, emphasizing the need to question personal interpretations of the Bible to align more closely with God's knowledge.Takeaways-To discern truth, one must eliminate opposing arguments.-Understanding the Bible requires questioning personal interpretations.-Faith involves a continuous process of learning and unlearning.-The knowledge of God is foundational to Christian beliefs.-Misinterpretations can lead to a skewed understanding of faith.-Engaging with scripture critically is essential for growth.-Personal biases can cloud one's understanding of biblical texts.-Community discussions can aid in better interpretations.-Faith is not static; it evolves with understanding.-True discernment comes from humility and openness.Chapters00:00 Discerning Truth in Faith00:06 Interpreting Biblical KnowledgeRumble Account: https://rumble.com/user/AshleyCampbellFacebook Page:https://www.facebook.com/dailyencouragementwithashleycampbell/Want to purchase a signed copy of mybook?https://buy.stripe.com/7sI8xdg6F2kZgSIfZ6ORRead the reviews on Amazon? https://a.co/d/gwyks9gWant to send me a financial donationbecause you value what I am doing on social media?https://buy.stripe.com/eVacNt3jTbVz9qg4gkWant to join my Facebook group thatwill equip you with the knowledge of the History of the United States, what the Constitution means and how you can preserve this great nation we live in?Join my paid group today! For only $10a month, you will have access to classes that will help you have the knowledge you need to save America!Group Link:https://www.facebook.com/share/RA7FqCx95Lbv5gWv/Group Payment link:https://buy.stripe.com/cN24gX07H4t70TKcMVPodcast links:Apple/I tunes:https://podcasts.apple.com/us/podcast/daily-encouragement-with-ashley-campbell/id1625607569Amazon Music:https://music.amazon.com/podcasts/4d32a7f2-1e3e-4045-aa13-2b77784c71d1/daily-encouragement-with-ashley-campbelliHeartRadiohttps://www.iheart.com/podcast/269-daily-encouragement-with-a-112334720/Overcast:https://overcast.fm/itunes1483675322/daily-encouragement-with-ashley-campbellRadio Public:https://radiopublic.com/daily-encouragement-with-ashley-c-WozzzRWant to sponsor the Podcast?https://buy.stripe.com/9AQbJpdYx8JnfOEfZ8Choose your amount to Sponsor the Podcast:https://donate.stripe.com/14k4gXg6F9Nr31SdR1

Description: Listen as NPF Medical Board Members, dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman discuss the connections between psoriasis and psoriatic arthritis, from cytokines to triggers, current and future treatments.   Join moderator Alan Simmons as he gains insights on what connects psoriasis and psoriatic arthritis with leading experts in psoriatic disease and NPF Medical Board members, dermatologist Dr. Robert Kalb with Buffalo Medical Group Dermatology, and rheumatologist Dr. Sergio Schwartzman from Schwartzman Rheumatology, as they discuss the known drivers of psoriasis and psoriatic arthritis, common triggers, benefits of targeted treatments, remission of disease, and upcoming treatment trends. The intent of this episode is to identify potential connections between psoriasis and psoriatic arthritis, and how targeted treatments have changed the outlook for management of psoriatic disease. This episode is sponsored by Novartis. Timestamps: (0:41) Intro to Psoriasis Uncovered and guest welcome dermatologist Dr. Robert Kalb and rheumatologist Dr. Sergio Schwartzman who are both involved in clinical care and research of psoriasis and psoriatic arthritis.  (1:15) Current known pro-inflammatory cytokines and cells found in psoriasis and psoriatic arthritis.   (5:33) Types of psoriasis that may lead to a higher risk of developing psoriatic arthritis. (9:33) Common triggers for psoriasis and psoriatic arthritis that could cause flares of the disease. (12:59) Key factors that are considered when choosing a treatment plan for any individual with psoriatic arthritis and psoriasis. (18:04) What treatment remission means for psoriasis. (19:36) Use of minimal disease activity (MDA) in psoriatic arthritis and what it means. (22:14) How a better understanding of the disease has led to more effective treatment choices and what choices are used by Dr. Kalb and Dr. Schwartzman for the management of psoriasis and psoriatic arthritis. (28:39) New developments in treatment and research in psoriatic arthritis and psoriasis. (36:01) Given treatment advancements it's a wonderful time to treat psoriatic disease. 3 Key Takeaways: ·       Cytokines are chemicals in the body that moderate various processes. In psoriasis and psoriatic arthritis,  an unknown trigger stimulates some cells to overproduce pro-inflammatory cytokines such as TNF-alpha, IL-17 or IL-23 leading to the development of skin and joint disease.  ·       Treating psoriasis and psoriatic arthritis helps move the body towards normalizing the over reactive immune system especially with more targeted treatments that safely and effectively block specific cytokines without affecting other organ systems.  ·       Given advancements in targeted treatments the goal is to reach and maintain remission of psoriatic disease. Guest Bios:   Leading dermatologist Robert Kalb, M.D. is the Chair of the Buffalo Medical Group Dermatology Department and the Director of the Buffalo Medical Group Phototherapy Center, one of the leading centers for psoriasis care in Western New York. He is also a Clinical Professor of Dermatology at the State University of New York at Buffalo School of Medicine and Biomedical Sciences (SUNY Buffalo), as well as an Adjunct Professor of Dermatology at the Perelman School of Medicine at the University of Pennsylvania where he plays a significant role in medical education, mentoring both medical students and dermatology residents. Dr. Kalb has extensive experience managing psoriasis, atopic dermatitis, and other inflammatory skin diseases. He has authored 70+ publications and is actively involved in clinical research, particularly focused on new treatment options for psoriasis. He is a member of the NPF Medical Board, American Academy of Dermatology, and is a member of the International Psoriasis Council.  Sergio Schwartzman, MD, is a world-renowned rheumatologist based in New York City who brings almost 40 years of experience and personalized clinical care for those who have psoriatic disease. Along with being in private practice at Schwartzman Rheumatology, Dr. Schwartzman is a Clinical Associate Professor of Medicine at Weill Cornell Medical College of Cornell University, the New York-Presbyterian Hospital, and the Hospital for Special Surgery in New York City where he has played a role in educating medical students, residents, fellows, and peers in rheumatology. Additionally, Dr. Schwartzman is the emeritus Franchellie M. Cadwell Clinical Associate Professor at the Hospital for Special Surgery. Dr. Schwartzman's current research interests include psoriatic arthritis, the spondyloarthritis group of diseases, ankylosing spondylitis, rheumatoid arthritis, as well as defining and treating autoimmune diseases of the eye. He has authored, co-authored, and edited over 150 papers, abstracts, books and book chapters on topics including psoriatic arthritis, ankylosing spondylitis, axial spondylarthritis, rheumatoid arthritis, lupus, autoimmune eye disorders, and other rheumatological and autoimmune conditions. He is a member of the NPF Medical Board. He is also a member of the American College of Rheumatology, the Association for Research in Vision and Ophthalmology, the Spondyloarthritis Research and Treatment Network (SPARTAN), the American Uveitis Society, and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Resources: Ø  “Redefining Remission. A new definition for patients, providers, and payers.” Advance Online, National Psoriasis Foundation. S. Schlosser. July 14, 2025.   Ø  Treatment and Management of Psoriasis     Ø  Treatment and Management of Psoriatic Arthritis  

In 2023, I was determined to have early Alzheimer's and was confirmed in early 2024 with a spinal tap. I began the newest treatment called Lecanemab and after 36 of those treatments and a recent PET scan and other tests, my doctor told me just an hour or so ago that my Alzheimer's is in remission. In fact, he said we don't even have a word for it, so we are using that word remission. Thanks be to God. #god #healing #jesus #alzheimer #remission #lecanemab Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

A meta-analysis of low-carb diets for diabetes remission found little to no effect at 12 months, clinically important harms to quality of life, and the deal-killer––an increase in LDL cholesterol.

On this episode of RNT Fitness Radio, I'm joined by long-time RNTer, Anila. Who, to be honest, is completely unrecognizable since where she started three years ago. Anila is down 30 kilos, but more than that her confidence has completely shot through the roof. Seeing her on a photo shoot day rocking outfits she probably never dreamed of and now just living life in a way that she didn't think was possible. Her type 2 diabetes has gone into remission and her health is in the best place it'sbeen. This is a really cool story and I can't wait to hear it.   Chapters: 00:00 Anila's Health Journey Begins 02:07 The Turning Point: Realizing the Need for Change 06:58 Finding the Right Program: R & T Fitness 09:45 The Initial Struggles and Learning Process 11:36 The Three-Year Transformation Journey 14:00 The Light Bulb Moment: Going All In 17:07 Support and Motivation: The Role of Pandian 19:12 Navigating the Consolidation Phase 21:07 Preparing for the Photo Shoot: Overcoming Self-Doubt 22:46 The Journey of Self-Discovery 24:08 Photo Shoot Experience and Confidence Building 26:07 Goals for Strength and Maintenance 30:18 Health Transformation and Remission 32:48 Mindset Shift and Overcoming Limitations 36:15 Impact on Motherhood and Self-Prioritization 39:11 Overcoming Fears and Setting Short-Term Goals 42:32 Final Thoughts and Encouragement   Next steps:  1) Apply for 1-1 coaching: https://www.rntfitness.co.uk/pro/   2) Take our quiz to see if you're ready for a transformation: http://www.rntfitness.co.uk/transform   3) Get our free book shipped to your door: https://bit.ly/tybtylform   4) Try our free 28 day fat loss accelerator: https://www.rntfitness.co.uk/transformation-accelerator  5) Optimum Nutrition: RNT20 for 20% off Connect with RNT Fitness:  Website  Facebook  Instagram  YouTube  Email  Connect with Akash:  Facebook  Instagram  LinkedIn 

A @Christadelphians Video: # SummaryThis presentation explores the fundamental principles of the Christian faith, particularly the doctrine of the Atonement. It delves into the biblical account of the Fall of man, the resulting sinful state of humanity, and the need for sacrifice and forgiveness as outlined in the Old Testament.Highlights

After two pregnancies—and nearly a year of feeling like she had the flu every day—Morgan (a pediatric cardiology professional and mom of two) was told “labs look normal.” Still, she had daily joint pain, low-grade fevers, shortness of breath, chest pain, dramatic weight loss, GI issues, and profound fatigue. In this raw and hopeful conversation, Dr. Isabelle Amigues shows what happens when a doctor truly listens, investigates beyond the surface, and aims for full remission—not 80%.If you've been dismissed, told to “wait it out,” or lost in the system, this episode is your proof: there is a path forward.What You'll LearnPostpartum red flags beyond “just thyroid”: when “normal labs” miss the full storyWhy low-grade daily fevers + severe fatigue should never be dismissedThe role of imaging and targeted therapy (incl. biologics) in speeding reliefHow mindset + clear plans (aiming for remission, not “good enough”) change outcomeThe difference time and listening make vs. quick, paperwork-driven visitsPractical ways to protect your energy and rebuild life after chronic symptomsWhy second (and third) opinions can be life-giving—and how to advocate for yourselfKey Topics CoveredMorgan's postpartum timeline: thyroiditis after baby #1 → much worse after baby #2The “normal labs” trap: significant symptoms with reassuring bloodworkDaily life on empty: parenting with profound fatigue, dizziness, and chest symptomsThe turning point: fevers as the objective sign that demanded deeper workupWhat felt different at UnabridgedMD: time, validation, a plan, and hopeTreatment philosophy: aim for 100%, iterate quickly if the first med isn't “the one”Mindset matters: keeping hope without denying reality (Isabelle's oncology lesson: “We're going for cure.”)Health system realities: too little time with patients, too much admin, and how listening saves time (and lives)Self-advice in hindsight: don't settle and guard your energyJoy returns: biking with kids, cooking, reconnecting—and rock climbing againGet in touch with guest Morgan: Morgan Town: Instagram @morgan.kaileyIf Morgan's story gave you hope, share this episode with a friend who's still searching for answers.Subscribe on YouTube for new episodes and practical remission-focused guidance.Have a question for Dr. Amigues? Comment on YouTube—we read every one.

The First Lady of Nutrition welcomes Lauren Vaknine, and for anyone living with rheumatoid arthritis, this is a story you won't want to miss. Diagnosed with juvenile RA just before her second birthday, Lauren was wheelchair-bound by 18 with every joint in her body locked. Most people would have lost hope—but not Lauren, and not her mother. Lauren's mom had already defied convention years earlier, saying no to steroids and choosing homeopathy instead. That decision opened the door to a lifetime of natural healing. At 21, Lauren had her own turning point: realizing her recovery was in her hands, she committed to rebuilding her health one choice at a time. Now, more than 11 years in remission, Lauren shares with Ann Louise the practices that made the difference—whole, organic foods instead of processed ones, key supplements like magnesium, cod liver oil, and black seed oil, and daily rituals with turmeric and frankincense that continue to keep her strong. From a child defined by illness to a global voice in holistic health, Lauren's message is both simple and powerful: the body knows how to heal when we give it what it needs. Learn more at laurenvaknine.co.uk The post From Rheumatoid Arthritis to Complete Remission: The Lauren Vaknine Story first appeared on Ann Louise Gittleman, PhD, CNS.

Send us a textDid you know you can be in remission and still have gut symptoms and fatigue? Medications may be addressing the inflammation - but they don't always fully address the symptoms.Sometimes you need to dig deeper with your dietitian on what nutrition related labs to run, looking into if you are fully meeting your needs and coming up with a plan and strategies to address gut symptoms.Takeaways-Remission does not always equate to feeling better.Nutritional deficiencies are common in IBD patients.Fatigue is a prevalent symptom even in remission.Hydration and electrolytes are crucial for energy levels.IBS can complicate the management of IBD symptoms.Energy management is key to improving quality of life.Long-term strategies are necessary for symptom relief for many.Dietary adjustments can help improve tolerance to foods.Follow us on instagram @crohns_and_colitis_dietitiansFollow us on youtube @thecrohnscolitisdietitiansWe love helping provide quality content on IBD nutrition and making it more accessible to all through our podcast, instagram and youtube channel. Creating the resources we provide comes at a significant cost to us. We dream of a day where we can provide even more free education, guidance and support to those with IBD like us. We need your support to do this. You can help us by liking episodes, sharing them on your social media, subscribing to you tube and telling others about us (your doctors, friends, family, forums/reddit etc). Can you do this for us? In return, I promise to continually level up what we do here.

Brenda Davis, R.D., shares groundbreaking insights into the effectiveness of plant-based nutrition for managing and reversing Type 2 Diabetes. Learn the science-backed benefits of adopting a plant-focused diet to restore health, improve blood sugar control, and transform your well-being. #PlantBasedDiet #DiabetesManagement #HealthyEating

Never miss another webinar! Signup here: https://imahealth.org/weekly-webinars/ Learn more: https://imahealth.org/stage-4-to-remissionHe was told he had less than a year to live. Now, he's here to tell the story of his incredible recovery. In this inspiring webinar, stage IV cancer survivor Dale Atkinson joins Dr. Amanda King, IMA Senior Fellow Dr. Kristina Carman, and host Dr. Paul Marik, IMA Co-Founder and Chief Scientific Officer, to share how integrative oncology helped him rewrite the ending.From devastating diagnosis to hope, Dale walks us through the treatments that made a difference, the turning points that kept him going, and the partnership with Dr. King that brought hope where there once was none. This isn't just a survivor story—it's a blueprint for blending conventional care with personalized, holistic approaches to chronic disease.• Donate: https://imahealth.org/donate/• Follow: https://imahealth.org/contact/• Webinar: https://imahealth.org/category/weekly-webinars/• Treatment: https://imahealth.org/treatment-protocols/• Medical Disclaimer: https://imahealth.org/about/terms-and-conditions/About IMA (Formerly FLCCC Alliance)The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system.For more information about the Independent Medical Alliance, visit www.IMAhealth.org

I sit down with Dr. Foran, an anesthesiologist and metabolic health practitioner who transformed her health through the carnivore diet. Dr. Foran opens up about her personal battle with ulcerative colitis and other autoimmune conditions, her experience on a vegan diet, and how embracing a carnivore lifestyle led her to not only regain her health ... Read more

On this special episode* of 'Rheumer has It', hosts Eileen and Cheryl are joined by renowned rheumatologist Dr. Loreto Carmona from Spain. The discussion centers around the concept of remission in rheumatoid arthritis (RA), highlighting the differences between medical and patient perspectives on what constitutes remission. Dr. Carmona emphasizes the importance of communication between patients and doctors, the role of medications and lifestyle factors, and the myths surrounding RA remission.This insightful conversation is part of the Canadian Talk Over RA campaign, aimed at providing hope and clear knowledge to those living with RA. See the full show notes on the Arthritis Life website for more details.Episode at a glance:00:31 Meet Dr. Loreto Carmona01:31 Defining Remission in Rheumatoid Arthritis04:26 Misconceptions About Remission07:38 Factors Influencing Remission11:30 The Importance of Communication14:48 Historical Perspectives on RA Treatment16:12 Final Thoughts and ResourcesMedical disclaimer:All content found on Arthritis Life public channels (including Rheumer Has It) was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.Episode SponsorsRheum to THRIVE, an online course and support program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected. See all the details and join the program or waitlist now!**Special Episode Sponsor: Talk Over RA CampaignAD - Talk Over RA is more than a campaign — it's a call to action. This podcast episode is part of the Talk Over RA 2025 campaign and is sponsored by AbbVie Canada. All content and opinions are Eileen Davidson, Cheryl Crow and Dr. Loreto's own and are not intended to promote any specific pharmaceutical products.Rheumatoid arthritis doesn't just speak through pain and fatigue — it interrupts plans, drains energy, and creates uncertainty even when symptoms are quiet. The Talk Over RA initiative encourages people living with RA to take back control by speaking up, sharing their experiences, and working with healthcare providers to set meaningful treatment goals.Eileen's role in this campaign is to provide tools that help you prepare for appointments, explore what remission could look like, and connect with others who truly understand.Don't let RA speak louder than you. Explore the campaign and download the guide here.For full episode show notesGo to the episode page on the Arthritis Life Website here. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

After experiencing stomach pains and fevers in the spring of 2023, Jordan Vanstee's then 2 year old son Kian was diagnosed with B Cell Acute Lymphoblastic Leukemia. Kian went through very difficult treatment at McMaster's Children's Hospital in Canada , but with the help of his Disney Hero Mickey Mouse and the Make a Wish Foundation, Kian is now in remission and is living his best life possible. 

In this week's episode of The Best Guest podcast we welcome The Brain Energy Reboot Expert, Moira Newiss.We talk about:Ketogenic & Metabolic Mental HealthMitochondria, Brain Energy & FatigueAutoimmune Conditions & the Carnivore DietAbout Moira NewissMoira Newiss is a BANT registered nutritional therapist, health coach and accredited ketogenic metabolic therapy expert who specialises in brain energy, one of the recently discovered root causes of many mental health problems.Moira's passion for metabolic mental health was sparked after a 20-year career as a senior NHS manager, managing hundreds of staff and multi-million-pound budgets. Following burnout, chronic fatigue and mental illness, she retrained at the Institute for Optimum Nutrition and became fascinated by the link between energy, mood, mental health and metabolic health. Moira works with individuals who have conditions including depression, anxiety, bipolar disorder, and schizophrenia, who have often not found a resolution with medication or psychological support alone. Her personalised approach has helped hundreds to improve their symptoms, with some achieving full remission, that means reversal, of their condition.A regular conference speaker, Moira co-authored the first mental health guidelines for nutritional therapists and published the case report ‘Remission of Schizophrenia Using a Carnivore Ketogenic Metabolic Therapy with Nutritional Therapy Practitioner Support'.Moira is lucky to live on the beautiful west coast of Scotland where she has a large garden, grows her own fruit and vegetables and has a lovely flock of hens. She also loves adventure, regularly climbing mountains, bike packing and hiking in remote spots on short expeditions. Key TakeawaysFor some people, shifting from glucose to ketone fuel can rapidly improve brain fog, mood, and energy.Common keto pitfalls include undereating fat and overeating proteinSleep, morning light, reduced evening blue light, and gentle movement support brain energy and mood.Short-term carnivore diet can be a powerful elimination protocol to calm inflammation, heal the gut and identify food triggers.Dairy-free keto is doable - use coconut fats, olive oil, tallow/lard, fatty fish; check labels on “milks” for hidden carbs.QuoteI had planned to do a hundred kilometre bike ride, and I remember crossing the finishing line thinking—and I was crying 'cause it was just an emotional thing—I just knew I cracked it. I just knew the energy was there. I'd cycled a hundred kilometres with no carbohydrates.Connect with Moira NewissWebsite: https://www.moiranewiss.co.uk/ Instagram: https://www.instagram.com/moiranewiss LinkedIn: https://www.linkedin.com/in/moira-newiss/ YouTube: https://www.youtube.com/@moiranewiss Connect with Victoria BennionLearn more about us: https://thebestpodcastguest.co.uk/Download our Podcast Guest Starter Kit: The Podcast Guest Starter Kit gives you a proven plan to find the right shows, craft a winning pitch, and maximise every interview.

What happens when someone living in and out of homelessness, battling schizophrenia, and cycling through hospitals and medications discovers ketogenic therapy?In this powerful interview, Dr. Bret Scher speaks with registered nutritional therapist Moira Newiss about one of the most remarkable published case reports to date.Despite overwhelming socioeconomic challenges, including periods of living in shelters and cooking on nothing more than a hot plate, this individual achieved sustained ketosis on a simple, affordable carnivore-based ketogenic diet.The result? His schizophrenia and psychosis went into remission.In the interview, Moira shares:The details of his journey from homelessness and hospitalization to stabilityThe simple, affordable foods he used to stay in ketosisThe barriers he faced, from relapse cycles to limited resourcesWhy this case matters for clinicians, researchers, and anyone seeking hope in the face of serious mental illnessThis case is more than a single success story, it challenges assumptions about what's possible with nutrition, even under the hardest circumstances. For someone who had been deeply embedded in psychiatric care in the UK and not improving on conventional treatment, ketogenic therapy offered a turning point.

In this episode of the UnabridgedMD Podcast, Dr. Isabelle Amigues sits down with Holly Gould to share her remarkable story of struggle, perseverance, and healing. After seeing more than a dozen doctors who couldn't provide answers, Holly felt she might never find relief. She recalls telling her husband, “If this person can't help me, I'll just have to live like this.” Out of options, she turned to Google—and that search led her to Dr. Amigues.Together, they explore what it means to be truly heard in a medical setting, how documenting every symptom—big and small—was key to unlocking proper treatment, and why compassionate follow-up, like Dr. Amigues' personal check-in call one week later, made all the difference. Holly describes how the right medication helped her day-to-day pain and how, for the first time in years, she sees a hopeful path toward remission.The conversation also highlights Dr. Amigues' philosophy: “Sometimes you can be a lot better, but it's not perfect. I want more than just a lot better.” For her, remission is always the goal—and fighting for her patients means never settling for less.Whether you're living with chronic illness, searching for a doctor who truly listens, or simply looking for hope in the healing journey, this episode offers compassion, empowerment, and a reminder that doctors who care are doctors who heal.Topics Covered:Why being truly heard matters in patient careThe turning point when Holly nearly gave up hopeHow documenting every symptom led to answersThe impact of personal follow-up calls from a doctorDr. Amigues' mission to help every patient reach remissionShifting from “just getting by” to true healingTune in to discover how persistence, compassion, and advocacy create the foundation for real healing—and why patients deserve more than “just a little better.”Thank you to special guest, Holly Gould, for sharing her story. Instagram: https://www.instagram.com/hollygould_realtor/ 

Are we living a life that reflects the forgiveness God has given?

In this episode of Leadership Bites, Guy Bloom interviews Erin Lee, the CEO of Flow Neuroscience, a company that has developed a wearable headset designed to treat depression through mild electrical stimulation of the brain. Erin shares her journey into the healthcare sector, the science behind the headset, and the promising results from clinical trials. The conversation explores the integration of Flow's technology with traditional treatments, the challenges faced in the medical community, and the potential future applications of this innovative approach to mental health. Erin emphasizes the importance of accessibility and affordability in mental health treatments, and the episode concludes with a call to action for listeners to explore Flow Neuroscience's offerings.TakeawaysErin Lee runs a neuroscience company that treats depression with electricity.The Flow headset is a wearable device that stimulates the brain.Clinical trials have shown a 75% drop in suicidal ideation.Erin's background includes experience in healthcare and tech companies.The headset works for 50-70% of users in treating depression.Flow can be used alongside traditional antidepressants.The technology aims to be accessible and affordable for all.Primary care clinicians are increasingly open to using Flow.The future of mental health treatment may include more personalized approaches.Flow is exploring applications for conditions like autism and ADHD.Sound Bites"We saw a 75% drop in suicidal ideation.""We can fit into a treatment for you that works.""We're not anti-drug, we're anti-depression."Chapters00:00 Introduction to Flow Neuroscience02:55 The Science Behind the Headset06:05 Erin's Journey to Flow Neuroscience08:48 The Founders and Their Vision12:03 Understanding the Technology14:49 Integration with Traditional Treatments17:46 The Future of Mental Health Treatment20:45 Educating Healthcare Professionals24:09 Strategic Targeting and Clinician Response26:53 Challenges in Primary Care vs Psychiatry29:50 The Role of Data in Treatment Effectiveness31:45 Exploring Applications in Autism and Neurodivergence34:01 The Future of Technology in Mental Health35:57 Understanding the Use of Flow for Well Individuals38:46 Integrating EEG for Personalized Treatment42:45 Concluding Thoughts and Future DirectionsTo find out more about Guy Bloom and his award winning work in Team Coaching, Leadership Development and Executive Coaching click below.The link to everything CLICK HEREUK: 07827 953814Email: guybloom@livingbrave.com Web: www.livingbrave.com

“That's the thing about music…it's time stamped…it's the soundtrack of our lives…especially for metal heads…”   The metal world mourns the tragic loss of another legend, and this one hit too close to home...    BRENT HINDS of Atlanta metal pioneers MASTODON was killed on August 20, 2025, in a traffic accident, just months after he and the band parted ways.   There is no other band on earth like MASTODON, and there will never be another guitar player like BRENT HINDS, and so with that, we give you our 2nd installment of MASTODON, focusing on their later work, from 2011's “The Hunter” to the final album to feature Hinds' contributions, the progressive double album opus, 2021's “Hushed And Grim”.   Discover why metal girls are so much better than girls who aren't into metal, learn the importance of spirit animals and shamans when traveling to other dimensions, and be sure to embrace the power of telepathy when communing with The Ineffable when you JOIN US as we bid farewell to BRENT HINDS and dig into the 2nd half of the MASTODON catalog with MASTODON CHAPTER II: 2010-2025.   Visit www.metalnerdery.com/podcast for more on this episode Help Support Metal Nerdery https://www.patreon.com/metalnerderypodcast Leave us a Voicemail to be played on a future episode: 980-666-8182 Metal Nerdery Tees and Hoodies – metalnerdery.com/merch and kindly leave us a review and/or rating on your favorite Podcast app Follow us on the Socials: Facebook - Instagram - TikTok Email: metalnerdery@gmail.com Can't be LOUD Enough Playlist on Spotify Metal Nerdery Munchies on YouTube @metalnerderypodcast Show Notes: (00:01): “The greatest misheard lyric…” / “It's really good…it's perfect…”/ “Looks…tastes…behaves like a peach…”/ ***WARNING: #listenerdiscretionisadvised *** / WELCOME BACK TO THE METAL NERDERY PODCAST IN BUNKERPOON 3-D DIGITAL!!! / #TheAverageDoubleteam / “Did you know, that if you take a tape measure…” / “She went to 73 inches…”/ #findyourage    (05:26): “Up to a point…which is the point of this episode…”/ #BrentHinds #RestInPeace / #allegedly / “Look twice, save lives…”/ “If you're not using your headphones with your phone in public, you're an asshole…”/ #onmicburp / “He said to do more, so I'm trying to…I'm working on it…I can only eat so much, I can only drink so much, but I'm doing my best…”/ #RussellsReflectionsBedtimeEdition / “I listen to #Slayer on my phone at the same volume…”   (12:52): PATREON SHOUT OUT: ***JOIN US on The Patreon at patreon.com/metalnerderypodcast *** / “See if you can guess what this is? EMAIL US at metalnerdery@gmail.com or VOICEMAIL US at 980-666-8182 and let us know if you know what this is? / “For somebody that doesn't like rap…”/ “You've gotta be careful, especially with Slayer lyrics…”   (15:51): #TheDocket METAL NERDERY PODCAST PRESENTS:  MASTODON VOL. II – 2010-2025: BRENT HINDS IN MEMORIAM / “He was as green as a lime…”/ #BloodMountain BLOOD MOUNTAIN (TRACK 1) / “That sounds like 1984…”/ “If you look at the first four albums, notice the logo…” / The impact of a band's logo & branding / “They always had a different logo…”/ “Glad you're excited bro, let's all fist together…”   (21:50): The Hunter (2011) / “Here's the hit…”/ CURL OF THE BURL / “It's got a #QOTSA vibe to it…”/ BLASTEROID / “Your first one?” / “That's the thing about music…it's time stamped…especially for metal heads…”/ “That's #boatmusic when I'm in the boat…”/ “We've got to…it's for us…it may not be your thing…”   (28:46): Once More ‘Round The Sun (2014) / “That album cover is DMT…”/ “What if Norm is Norvyn?” / “If you've ever done DMT…that's what it looks like…”/ #RussellsReflectionsDMTASMR / “He didn't charge us…”/ “It tastes like smoking a tire…”/ “The best way I can describe it…”/ “You've gotta come see this…”/ “It was talking to her in a language she didn't understand…”/ #TheIneffable / “Keep doing what you're doing, I'll see you in about…”/ “And we're back…”/ THE MOTHERLOAD / “Listen to this riff… / AUNT LISA / #Fucking / “Every time I listen to #Mastodon I'm so confused…”/ “Remission and Leviathan were sludge thrash…”   (43:43): Emperor of Sand (2017) / “You know the cool thing about Bells…”/ “She's the first girl I ever met who loved Slayer as much as I did…”/ “Andi with an I? Oooooooh, you know what that means, right?” / STEAMBREATHER / “They make the best music videos…”/ #redudeulous / SHOW YOURSELF / “How is Mastodon gonna sound going forward?”   (51:20): Hushed And Grim (2021) / THE CRUX / “When it kicks in, it's kicking…”/ PEACE AND TRANQUILITY / “Here's what we should end on…”/ “Shut up…”/ Did y'all hear that? / #AdultSwim DEATHBOUND / “WTF is that?” / #technicaldifficulties #WTF #ParanormalASMR #untilthenext #outroreel 

Discover how fear, doubt, unspoken emotions, and embracing death can directly impact your immune system—and what you can do today to support healing from cancer, ALS, MS, Parkinson's, Alzheimer's, lupus, heart failure, and other serious conditions.In this episode of Renegade Remission, we explore the profound connection between emotional health and physical wellness, and how suppressing feelings like fear, doubt, or grief can negatively impact your immune system. Using compelling case studies, including the story of Daniel, whose aggressive cancer unexpectedly regressed, we uncover how embracing emotions, facing fear, and living purposefully can support your body's natural ability to heal.This episode is for anyone facing a terminal or chronic diagnosis—including cancer, ALS, MS, Parkinson's, Alzheimer's, lupus, heart failure, and other serious conditions—or for caregivers seeking actionable insights. Learn why emotional expression is essential, how your nervous and immune systems are interconnected, and three practical steps you can implement today to improve your emotional and physical health.

After experiencing a persistent cough and a pain in his side, Keith Jay of Texas was encouraged to seek medical advice. Although it took a few months, in November of 2024 he was diagnosed with stage 4 lung cancer that had metastasized to his lymph glands, bones and spine. Refusing chemotherapy, a friend encouraged him to contact Corrie Yelland who told him about cannabis oil. Nine months later he is cancer free. A truly inspirational story. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover

Think there's nothing more you can do after a terminal diagnosis? Welcome to Renegade Remission—the podcast that busts myths about spontaneous remission, shares the science behind unexpected healing, and shows how you can take practical steps to improve your health and wellbeing. Real stories, real strategies, and real hope—this is your guide to reclaiming agency over your life.

In this first episode of Renegade Remission, I introduce the new direction of the podcast and explain why it's focused on helping people facing terminal diagnoses reclaim agency over their health. We bust common myths about spontaneous remission, explore the surprising science behind unexpected healing, and clarify what this podcast is—and isn't. You'll learn how understanding the mind-body connection, emotions, and lifestyle factors can empower you to improve quality and quantity of life, even in the face of a serious diagnosis.

Leading dermatologist and NPF Medical Board Member, Dr. Tina Bhutani, and Gail Reiser who lives with plaque psoriasis discuss what “on treatment remission” means for those who have the disease and health care providers.   Join moderator and resident physician Olivia Kam as she discusses the definition of on treatment remission for plaque psoriasis, and how this definition impacts the management of the disease and when to change treatments with leading dermatologist Dr. Tina Bhutani from Synergy Dermatology in San Francisco, and Gail Reiser who has been living with plaque psoriasis for over 42 years experiencing a variety of treatment options.  The intent of this episode is to increase knowledge of the latest consensus statement defining what “on treatment remission” means in the context of managing plaque psoriasis and how such information can be used to guide patient/provider discussion and setting treatment goals. This episode is sponsored by AbbVie. Timestamps: (0:23) Intro to Psoriasis Uncovered and guest welcome dermatologist Dr. Tina Bhutani and Gail, who has been living with plaque psoriasis for over 42 years. (1:56) Definition of “on treatment remission” and development of this unified consensus statement that included almost 100 stakeholders. (3:28) How the definition of “on treatment remission” impacts management of psoriasis. (5:09) A patient's perspective about “on treatment remission” and what it means for future care. (8:57) Assessing when a change in treatment may be appropriate.   (11:19) What information a dermatologist can provide to assess if treatment is effective. (14:20) Prioritizing what to discuss with a dermatologist or health care provider. (17:21) Call to action for dermatologists from the “On Treatment Remission” consensus statement. (20:37) Advice for discussing treatment goals as a patient and health care provider. Key Takeaways: ·       A new consensus statement helps define and standardize what “On Treatment Remission” is and what it means for patient care. ·       Given current treatment options it is possible to reach skin clearance and on treatment remission. ·       Having standardized goals makes it easier for health care providers and patients who have psoriatic disease to work together to reach on treatment remission. Guest Bios:   Tina Bhutani, M.D., MAS, is a board-certified dermatologist who is the CEO and owner of Synergy Dermatology in San Francisco. Dr. Bhutani is also an Associate Clinical Professor of Dermatology at UCSF where she previously co-directed the Psoriasis and Skin Treatment Center and directed the Clinical Trials Unit for over 8 years. Dr. Bhutani understands the importance of treating the whole patient and is committed to a patient-centered approach to dermatology. She is a recognized leader in dermatology, giving talks at many national and international meetings. Dr. Bhutani is a member of the National Psoriasis Foundation Medical Board who recently published a consensus statement called “Defining On Treatment Remission in Plaque Psoriasis” in JAMA Dermatology. Gail Reiser was initially diagnosed with plaque psoriasis at age 12. She remembers the misdiagnoses and difficult treatments of the past such as coal tar and occlusion. Over 42 years of living with plaque psoriasis, Gail has experienced a variety of treatment options including topicals and light therapy, feeling “it is exhausting to treat psoriasis”. As she got older and her plaque psoriasis progressed, she eventually decided to try biologics and hasn't looked back since making that change. She feels her psoriasis is in remission but fears losing that in the future.  Resources: “Redefining Remission. A new definition for patients, providers, and payers.” Advance Online, National Psoriasis Foundation. S. Schlosser. July 14, 2025. To hear other perspectives about living with psoriasis through the resource Gail mentioned: MyPsoriasisTeam.  Treatment and Management of Psoriasis

Rachel Cook Northway shares with me her personal journey to clean beauty. Her childhood interest in skincare was already influenced by her mother's beauty routine. After an early career in the nonprofit sector, Rachel transitioned into the clean beauty industry and worked with various brands and retailers. And built her expertise and passion.When she was pregnant with her second child, she was diagnosed with breast cancer. This experience propelled her to launch her own business post-remission. Rachel is helping women (and men) to navigate and personalise the clean beauty space.Her beauty philosophy and recommendations are simple but efficient: focus on lips, eyes and underarms as key areas for clean product adoption. She emphasizes efficacy and plant-based alternatives in clean beauty. And has a range of brands that she recommends and curates for individual needs.Rachel also advocates for occasional breaks from deodorant use, especially for breast cancer survivors.Her daily rituals for her personal wellness and recovery are morning prayers, co-sleeping with her youngest child, intermittend fasting and a plant-basesd diet. And she is avid in her workout routine on 6 times per week.For her business she is planning on expanding into her own studio space to receive clients in person. She also feels that it is important to refine the language clean beauty, to emphasize wellness over appearance standards. To learn more about my guest Rachel Cook Northway, please visit her social media pages:Instagram: @thenorthwayeditWebsite: The Northway EditTo learn more about SHIFT HAPPENS, click here To learn more about Claudia's business Curated Conversations and her Salons in New York, Zurich and Berlin, click hereYou can also connect with Claudia on Instagram @shifthappens.podcast and LinkedIn at ClaudiaMahlerNYCThis podcast is created, produced and hosted by Claudia Mahler.Social Media support Magdalena Reckendrees

Rheumatologists Dr Anca Askanase and Dr Cristina Arriens discuss their clinical perspectives on how to target and achieve DORIS remission in clinical practice. Sponsored by AstraZeneca Medical Affairs

This week on the Tom Roland podcast, I sit down with John Gluck, the author of 'An Exercise in Uncertainty.' We dive deep into discussions about fishing, life, and John's incredible journey battling Multiple Myeloma—a rare blood cancer.  Diagnosed with only 18 months to live, John has now thrived for over 21 years, thanks in part to breakthrough treatments and his passion for fishing. We also explore how fishing became a therapeutic escape for John, the power of mindset in overcoming challenges, and the role of family and career in his ongoing battle.  Tune in to hear this inspiring story and learn from John's experiences. You can also buy Jonathan's book, “An Exercise in Uncertainty” wherever books are sold.  00:00 Introduction and Greetings 00:18 Fishing in Idaho and Jackson 00:47 The Glory Days of Fishing 01:16 Challenges of the Salmon Fly Hatch 02:54 Introducing the Book: An Exercise in Uncertainty 03:17 John's Illness and Diagnosis 03:51 Fishing as a Lifeline 04:47 Writing and Fishing Adventures 08:17 Career and Writing Focus 10:23 The Diagnosis Journey 18:26 Coping with Uncertainty 26:02 Purpose and Priorities 29:10 Fishing Dreams and Realities 33:25 Reflections on Health and Life 35:42 Facing Mortality and Embracing Life 36:45 Dealing with Remission and Relapse 39:22 Finding Solace in Fishing 42:36 The Role of Diet and Exercise 44:56 Advice for Cancer Patients 48:08 Writing the Book: A Journey of Reflection 53:53 The Importance of Mindset 01:05:08 Publishing and Promoting the Book 01:13:12 Final Thoughts and Future Plans